NCT07149402Not yet recruiting
Association of Serum Interleukin-33 Levels With Clinical Manifestations in Systemic Lupus Erythematosus
Serum Interleukin-33 (IL-33) Levels and Their Association With Clinical Manifestations in Patients With Systemic Lupus Erythematosus and Lupus Nephritis at Assiut University Hospital
Source: ClinicalTrials.gov · Last updated 2 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a case-control study investigating serum IL-33 levels and their association with clinical manifestations in systemic lupus erythematosus (SLE). The study compares IL-33 levels in three groups: SLE patients with lupus nephritis, SLE patients without nephritis, and healthy controls. The goal is to clarify IL-33's role as a biomarker reflecting disease activity and organ involvement, especially renal pathology.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 28 Aug 2025
- Start date
- 30 Aug 2026
- Primary completion date
- 30 Oct 2027
- Lead sponsor
- Assiut University
- Diseases
- Lupus (SLE)
- NCT number
- NCT07149402
What you commit to
- Study type: Observational
- Planned participants: 150
- From 30 Aug 2026 to the primary completion date, 30 Oct 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with other autoimmune diseases. Patients with chronic infections or malignancies. Pregnant or lactating women. Patients with end-stage renal disease (ESRD) or on dialysis. Individuals who refuse to provide informed consent.
Who the study is looking for
- Adults aged 18 years and older.
- Diagnosed with systemic lupus erythematosus according to the American College of Rheumatology (ACR) criteria.
- For the lupus nephritis group: confirmed diagnosis of lupus nephritis based on clinical, laboratory, and renal biopsy findings.
- For the control group: healthy individuals matched for age and sex, with no history of autoimmune or renal diseases.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.